Abstracts

DOXYPEP & ANTIMICROBIAL RESISTANCE IN N. GONORRHOEAE, COMMENSAL NEISSERIA & S. AUREUS

Background: Doxycycline post-exposure prophylaxis (doxy-PEP) is highly effective in reducing N. gonorrhoeae (GC), C. trachomatis (CT), and syphilis among men who have sex with men (MSM) and transgender women (TGW). Understanding the effect of doxy-PEP use on antimicrobial resistance (AMR) in N.gonorrhoeae and bacteria which can cause disease (S.aureus) or transmit resistance (Neisseria spp) is…

PREDICTORS OF HEPATITIS B TREATMENT RESPONSE IN PEOPLE WITH HIV/HBV COINFECTION

Background: Response to hepatitis B treatment in people with HIV-1/HBV varies by baseline (BL) HBV DNA level and HBeAg status. Here we present a subanalysis of 48W outcomes from a phase 3 study (ALLIANCE) comparing bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) vs dolutegravir + emtricitabine/tenofovir disoproxil fumarate (DTG+F/TDF) in participants initiating treatment for HIV-1 and HBV to examine…

PanACEA SUDOCU COMBINATION DOSE-FINDING TRIAL SHOWS SUTEZOLID IS A SAFE OXAZOLIDINONE

Background: Linezolid is a critical component of current MDR-TB treatment, but is too toxic for wider use. Sutezolid is a novel oxazolidinone, with a hypothesized improved safety profile. Sutezolid was previously only clinically tested in a 14-day monotherapy study. Methods: The PanACEA Sutezolid Dose-Finding and Combination Evaluation (SUDOCU) study was a novel approach at defining…

EFFICACY AND SAFETY OF 8-WK TUBERCULOSIS TREATMENT REGIMENS IN THE TRUNCATE-TB TRIAL

Background: The TRUNCATE-TB trial (NCT03474198) found that the TRUNCATE strategy – initial treatment for 8 weeks (with BDQ/LZD regimen; extended up to 12 weeks for unsatisfactory clinical response); post-treatment follow-up; prompt retreatment (standard regimen) for relapse – was non-inferior to the standard treatment strategy at 96 weeks. Here we analyse efficacy and safety of the…